Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1969 1
1970 3
1972 3
1973 2
1975 2
1976 1
1978 4
1980 1
1981 5
1982 2
1983 1
1984 3
1985 3
1986 4
1987 11
1988 4
1989 2
1990 2
1991 3
1992 2
1993 2
1994 1
1995 4
1996 2
1997 2
1998 1
1999 1
2000 3
2001 3
2002 2
2003 2
2004 4
2005 3
2006 3
2007 2
2008 2
2009 4
2010 4
2011 1
2012 5
2013 4
2014 9
2015 7
2016 3
2017 2
2018 4
2019 2
2020 1
2021 3
2022 1
2023 0
Text availability
Article attribute
Article type
Publication date

Search Results

143 results
Results by year
Filters applied: Meta-Analysis, Randomized Controlled Trial. Clear all
Page 1
Mucolytics for bronchiectasis.
Wilkinson M, Sugumar K, Milan SJ, Hart A, Crockett A, Crossingham I. Wilkinson M, et al. Cochrane Database Syst Rev. 2014 May 2;2014(5):CD001289. doi: 10.1002/14651858.CD001289.pub2. Cochrane Database Syst Rev. 2014. PMID: 24789119 Free PMC article. Review.
A reduction in sputum production was noted with bromhexine (MD -21.5%, 95% CI -38.9 to -4.1 at day 16); again the quality of the evidence was rated as low. ...As the number of agents available on the market, such as RhDNase, acetylcysteine and bromhexine, is increas …
A reduction in sputum production was noted with bromhexine (MD -21.5%, 95% CI -38.9 to -4.1 at day 16); again the quality of the evid …
Bromhexine Hydrochloride Tablets for the Treatment of Moderate COVID-19: An Open-Label Randomized Controlled Pilot Study.
Li T, Sun L, Zhang W, Zheng C, Jiang C, Chen M, Chen D, Dai Z, Bao S, Shen X. Li T, et al. Clin Transl Sci. 2020 Nov;13(6):1096-1102. doi: 10.1111/cts.12881. Epub 2020 Oct 10. Clin Transl Sci. 2020. PMID: 32881359 Free PMC article. Clinical Trial.
This open-label randomized controlled pilot study aimed to test the study feasibility of bromhexine hydrochloride (BRH) tablets for the treatment of mild or moderate coronavirus disease 2019 (COVID-19) and to explore its clinical efficacy and safety. ...
This open-label randomized controlled pilot study aimed to test the study feasibility of bromhexine hydrochloride (BRH) tablets for t …
Bromhexine in chronic bronchitis.
Christensen F, Kjer J, Ryskjaer S, Arseth-Hansen P. Christensen F, et al. Br Med J. 1970 Oct 10;4(5727):117. doi: 10.1136/bmj.4.5727.117-a. Br Med J. 1970. PMID: 4919405 Free PMC article. Clinical Trial. No abstract available.
Ambroxol as a novel disease-modifying treatment for Parkinson's disease dementia: protocol for a single-centre, randomized, double-blind, placebo-controlled trial.
Silveira CRA, MacKinley J, Coleman K, Li Z, Finger E, Bartha R, Morrow SA, Wells J, Borrie M, Tirona RG, Rupar CA, Zou G, Hegele RA, Mahuran D, MacDonald P, Jenkins ME, Jog M, Pasternak SH. Silveira CRA, et al. BMC Neurol. 2019 Feb 9;19(1):20. doi: 10.1186/s12883-019-1252-3. BMC Neurol. 2019. PMID: 30738426 Free PMC article. Clinical Trial.
Bromhexine in the treatment of otitis media with effusion.
Stewart IA, Guy AM, Allison RS, Thomson NJ. Stewart IA, et al. Clin Otolaryngol Allied Sci. 1985 Jun;10(3):145-9. doi: 10.1111/j.1365-2273.1985.tb01183.x. Clin Otolaryngol Allied Sci. 1985. PMID: 3896583 Clinical Trial.
There were 198 ears in the placebo group and 182 ears in the bromhexine group. The resolution rate in the placebo treated group was 19% and in the bromhexine treated group 16%. Bromhexine does not appear to be a useful drug for the treatment of OME in childre …
There were 198 ears in the placebo group and 182 ears in the bromhexine group. The resolution rate in the placebo treated group was 1 …
New prophylaxis regimen for SARS-CoV-2 infection in health professionals with low doses of hydroxychloroquine and bromhexine: a randomised, double-blind placebo clinical trial (ELEVATE Trial).
Granados-Montiel J, Hazan-Lasri E, Franco-Cendejas R, Chávez-Heres T, Silva-Bermudez P, Aguilar-Gaytán R, Manzano-León N, Méndez-Maldonado K, Alvarez-Arce A, Martínez-Portilla RJ. Granados-Montiel J, et al. BMJ Open. 2021 Aug 3;11(8):e045190. doi: 10.1136/bmjopen-2020-045190. BMJ Open. 2021. PMID: 34344672 Free PMC article. Clinical Trial.
We propose studying prophylactic treatment with hydroxychloroquine (HCQ) and bromhexine (BHH), which have been shown to be effective in preventing SARS-CoV-2 infection progression when administered in early stages. ...
We propose studying prophylactic treatment with hydroxychloroquine (HCQ) and bromhexine (BHH), which have been shown to be effective …
Bioavailability of bromhexine tablets and preliminary pharmacokinetics in humans.
Bechgaard E, Nielsen A. Bechgaard E, et al. Biopharm Drug Dispos. 1982 Oct-Dec;3(4):337-44. doi: 10.1002/bdd.2510030407. Biopharm Drug Dispos. 1982. PMID: 6897618 Clinical Trial.
The absorption of bromhexine from Bromhexin tablets 8 mg, DAK has been compared with that from Bisolvon tablets 8 mg, Boehringer Ingelheim, in a two-way complete crossover study. Four tablets of each of the two bromhexine products, corresponding to a single d …
The absorption of bromhexine from Bromhexin tablets 8 mg, DAK has been compared with that from Bisolvon tablets 8 mg, Boehring …
Bromhexine treatment of Sjögren's syndrome: effect on lacrimal and salivary secretion, and on proteins in tear fluid and saliva.
Manthorpe R, Frost-Larsen K, Høj L, Isager H, Prause JU. Manthorpe R, et al. Scand J Rheumatol. 1981;10(3):177-80. doi: 10.3109/03009748109095294. Scand J Rheumatol. 1981. PMID: 7027431 Clinical Trial.
Bromhexine stimulated the tear secretion significantly, presumable without changing the protein composition of the tear fluid. In contrast to other proteins in saliva the IgM concentration decreased in patients with high pre-treatment values. Bromhexine may be of va
Bromhexine stimulated the tear secretion significantly, presumable without changing the protein composition of the tear fluid. In con
Sjörgren's syndrome treated with bromhexine: a randomised clinical study.
Frost-Larsen K, Isager H, Manthorpe R. Frost-Larsen K, et al. Br Med J. 1978 Jun 17;1(6127):1579-81. doi: 10.1136/bmj.1.6127.1579. Br Med J. 1978. PMID: 350346 Free PMC article. Clinical Trial.
In the first trial bromhexine 24 mg/day was given by mouth; in the second the dose was increased to 48 mg/day. ...It had no effect on salivary gland function. Bromhexine is therefore valuable in the treatment of Sjogren's syndrome....
In the first trial bromhexine 24 mg/day was given by mouth; in the second the dose was increased to 48 mg/day. ...It had no effect on …
Bromhexine in severe asthma.
Rudolf M, Riordan JF, Grant BJ, Maberly DJ, Saunders KB. Rudolf M, et al. Br J Dis Chest. 1978 Oct;72(4):307-12. Br J Dis Chest. 1978. PMID: 365213 Clinical Trial.
Fourteen patients with acute severe asthma necessitating hospital admission were all treated with a standard therapeutic regimen, and in addition received either bromhexine or placebo (initially intravenously and subsequently orally) double-blind. We were unable to show an …
Fourteen patients with acute severe asthma necessitating hospital admission were all treated with a standard therapeutic regimen, and in add …
143 results